Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.67 |
| ▸ | ALOX5AP | P20292 | 17/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | RECQL | P46063 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181651 | 1.00 | PTGES2 (0.67) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL12014950 | 0.94 | ALOX5AP (0.58) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL1255386 | 0.92 | PTGES2 (0.56) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL9044184 | 0.92 | PTGES2 (0.78) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL25968196 | 0.90 | PTGES2 (0.67) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL167199 | 0.89 | PTGES2 (0.66) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL1192956 | 0.89 | ALOX5AP (0.81) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL23270814 | 0.89 | ALOX5AP (0.73) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL30181492 | 0.89 | ALOX5AP (0.73) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL30181605 | 0.89 | ALOX5AP (0.79) | PTGES2ALOX5APALOX5CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-113329996-B | Compounds and methods for treating hedgehog pathway related disorders | 博远医药(苏州)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3810573-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | Suzhou Mednes Pharma Tech Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | disclosed |
| US-8841295-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1943219-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-5420282-A | Inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1995-05-30 | — | — | US | disclosed |
| US-5399699-A | Lipoxygenase inihibitors, antiallergens, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1994012179-A1 | INDOLE CARBOXYLATE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5288743-A | Lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885 |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885 |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | LTC4S, ALOX5, LTA4H | PTGES2 19/4885ALOX5AP 6/4885ALOX5 2/4885 |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | PTGES2 1332/4885ALOX5AP 3783/4885ALOX5 1983/4885 |
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | PTGES2 1476/4885ALOX5AP 3709/4885ALOX5 1833/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | PTGES2 21/4885ALOX5AP 35/4885ALOX5 7/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | PTGES2 1332/4885ALOX5AP 3783/4885ALOX5 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.